Disease: Metastatic melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 12960123 2003
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma. 12873977 2003
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patients with (V599E)BRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host. 15289355 2004
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF mutation was present in 15 of 23 (61%) patients with primary melanoma and in 7 of 12 (58%) patients with metastatic melanoma. 16096377 2005
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE These data demonstrate the feasibility of blood-based testing for BRAF mutations in metastatic melanoma patients. 17384209 2007
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE In this study, we evaluated the efficacy of targeting either B-Raf or IKKbeta in combination with the DNA alkylating agent temozolomide for treatment of advanced metastatic melanoma. 19276165 2009
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Nuclear factor of activated T-cells transcriptional activity and protein expression were determined in three human metastatic melanoma cell lines with differing B-RAF mutational status. 19724275 2009
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE Clinicians should be aware of phase 3 trials of these agents and trials combining these therapies with other novel therapies because, at a minimum, BRAF inhibitors seem to be valuable as palliative therapy for metastatic melanoma. 21041578 2010
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 additional patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase. 20818844 2010
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE The interval from diagnosis of first-ever melanoma to distant metastasis was not significantly different between BRAF-mutant and BRAF wild-type patients; however, the median survival of patients with newly diagnosed metastatic melanoma was 5.7 months for BRAF-mutant patients not treated with a BRAF inhibitor, 8.5 months for BRAF wild-type patients, and not reached for BRAF-mutant patients treated with a BRAF inhibitor. 21343559 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. 21639808 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation. 22037033 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. 21139585 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE The results suggest that we have entered an era of personalized therapy for patients with metastatic melanoma in which treatment selection will be guided by BRAF mutational status. 21997758 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. 22028422 2011
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Tissue samples obtained from EBUS TBNA are adequate to diagnose metastatic melanoma in hilar and mediastinal lymph nodes and to detect the presence or absence of mutations in the BRAF gene. 22617000 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. 22356324 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Dideoxy sequencing and fluorescent single strand conformation analysis were used to screen for mutations in exon 15 of BRAF in 183 cases of metastatic melanoma. 22614711 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Following Phase I and II studies revealing vemurafenib to be a safe potent inhibitor of mutated BRAF in patients with metastatic melanoma, a multicenter randomized Phase III trial was carried out to compare vemurafenib with dacarbazine in treatment-naive patients. 22646765 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE Clinical trials with BRAF inhibitor vemurafenib have shown objective clinical response and improved survival in patients with MM; therefore, knowledge of the molecular signature of melanoma in patients will be important in directing management decisions. 23174497 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. 22804352 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE Taken together, our findings, derived from 2 independent models combining BRAF-targeted therapy with immunotherapy, support the testing of this therapeutic combination in patients with BRAFV600 mutant metastatic melanoma. 22693252 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the US Food and Drug Administration to select patients with BRAF-mutant metastatic melanoma for treatment with the BRAF inhibitor vemurafenib. 22332713 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE Following a rapid clinical development path, vemurafenib (Zelboraf; Plexxikon/Roche) was approved for the treatment of BRAF-mutated metastatic melanoma in the United States in August 2011 and the European Union in February 2012. 23060265 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE Recent advances in the treatment of metastatic melanoma with BRAF and KIT inhibitors have increased the demand for molecular testing in melanoma. 22619125 2012